Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types
- 1 August 2010
- journal article
- Published by SAGE Publications in Genes & Cancer
- Vol. 1 (8), 812-821
- https://doi.org/10.1177/1947601910383418
Abstract
Poly (ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair and is implicated in pathways of tumorigenesis. PARP inhibitors have gained recent attention as rationally designed therapeutics for the treatment of several malignancies, particularly those associated with dysfunctional DNA repair pathways, including triple-negative breast cancer (TNBC). We investigated the PARP1 gene expression profile in surgical samples from more than 8,000 primary malignant and normal human tissues. PARP1 expression was found to be significantly increased in several malignant tissues, including those isolated from patients with breast, uterine, lung, ovarian, and skin cancers, and non-Hodgkin's lymphoma. Within breast infiltrating ductal carcinoma (IDC) samples tested, mean PARP1 expression was significantly higher relative to normal breast tissue, with over 30% of IDC samples demonstrating upregulation of PARP1, compared with 2.9% of normal tissues. Because of known DNA repair defects, including BRCA1 dysfunction, associated with TNBC, exploration of PARP1 expression in breast cancers related to expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) led to the observation that negative expression of any of the 3 receptors was associated with upregulation of PARP1 expression, compared with receptor-positive tissues. To validate these observations, an independent set of breast adenocarcinomas was evaluated and demonstrated >2-fold upregulation of PARP1 in approximately 70% of primary breast adenocarcinomas, including TNBC, compared with syngeneic nonmalignant breast tissues. Immunohistochemistry (IHC) showed that upregulation of the PARP1 gene was consistent with increased protein expression in TNBC. These analyses suggest a potential biological role for PARP1 in several distinct malignancies, including TNBC. Further investigation of PARP1 as a biomarker for the therapeutic activity of PARP inhibitor-based therapy is warranted.Keywords
This publication has 40 references indexed in Scilit:
- Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor StatusJNCI Journal of the National Cancer Institute, 2007
- Triple-negative breast cancer: therapeutic optionsThe Lancet Oncology, 2007
- The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stabilityOncogene, 2006
- Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase InhibitionCancer Research, 2006
- Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signalGenes & Development, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Regulation of BRCC, a Holoenzyme Complex Containing BRCA1 and BRCA2, by a Signalosome-like Subunit and Its Role in DNA RepairMolecular Cell, 2003
- PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) PolymerasePublished by Elsevier BV ,1999
- CA 125 in Ovarian Cancer: Advances and ControversyClinical Chemistry, 1998
- Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancersCancer Letters, 1991